Deucrictibant

5 trials 3 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

1 Sponsors

14 Countries

Phase III

Phase II/III

Phase III: 4 Phase II/III: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Hereditary angioedema 2 Acquired C1 inhibitor deficiency 1

Sponsors using this IMP

Pharvaris Netherlands B.V. 5

All trials

5 total

Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On-demand Treatment of Angioedema Attacks in Adults with Acq… Recruiting

2025-522051-26-00 Phase III 9 countries Pharvaris Netherlands B.V.
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Phase II/III 14 countries Pharvaris Netherlands B.V.
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Phase III 11 countries Pharvaris Netherlands B.V.
CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult… Ended

2024-516247-62-00 Phase III 10 countries Pharvaris Netherlands B.V.
A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu… Ended

2023-507268-37-00 Phase III 14 countries Pharvaris Netherlands B.V.

Showing 1–5 of 5 trials

← All drugs A–Z